tetano
Editor, Senior Moderator
Eurosurveillance, Volume 20, Issue 36, 10 September 2015
Surveillance and outbreak report
Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results
R Pebody [SUP]1[/SUP] , F Warburton [SUP]1[/SUP] , N Andrews [SUP]1[/SUP] , J Ellis [SUP]1[/SUP] , B von Wissmann [SUP]2[/SUP] , C Robertson [SUP]3[/SUP] , I Yonova [SUP]4[/SUP] [SUP]5[/SUP] , S Cottrell [SUP]6[/SUP] , N Gallagher [SUP]7[/SUP] , H Green [SUP]1[/SUP] , C Thompson [SUP]1[/SUP] , M Galiano [SUP]1[/SUP] , D Marques [SUP]2[/SUP] , R Gunson [SUP]2[/SUP] , A Reynolds [SUP]2[/SUP] , C Moore [SUP]6[/SUP] , D Mullett [SUP]4[/SUP] [SUP]5[/SUP] , S Pathirannehelage [SUP]4[/SUP] [SUP]5[/SUP] , M Donati [SUP]1[/SUP] , J Johnston [SUP]7[/SUP] , S de Lusignan [SUP]4[/SUP] [SUP]5[/SUP] , J McMenamin [SUP]2[/SUP] , M Zambon [SUP]1[/SUP]
+ Author affiliations
1. Public Health England, England, United Kingdom
2. Health Protection Scotland, Scotland, United Kingdom
3. University of Strathclyde, Scotland, United Kingdom
4. RCGP Research and Surveillance Centre, England, United Kingdom
5. University of Surrey, England, United Kingdom
6. Public Health Wales, Wales, United Kingdom
7. Public Health Agency Northern Ireland, Northern Ireland, United Kingdom
Correspondence: Richard Pebody (richard.pebody@phe.gov.uk)
Citation style for this article: Pebody R, Warburton F, Andrews N, Ellis J, von Wissmann B, Robertson C, Yonova I, Cottrell S, Gallagher N, Green H, Thompson C, Galiano M, Marques D, Gunson R, Reynolds A, Moore C, Mullett D, Pathirannehelage S, Donati M, Johnston J, de Lusignan S, McMenamin J, Zambon M. Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results. Euro Surveill. 2015;20(36)
ii=30013. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2015.20.36.30013
Received:16 June 2015; Accepted:31 August 2015
[h=4][/h]
The 2014/15 influenza season in the United Kingdom (UK) was characterised by circulation of predominantly antigenically and genetically drifted influenza A(H3N2) and B viruses. A universal paediatric influenza vaccination programme using a quadrivalent live attenuated influenza vaccine (LAIV) has recently been introduced in the UK. This study aims to measure the end-of-season influenza vaccine effectiveness (VE), including for LAIV, using the test negative case?control design. The overall adjusted VE against all influenza was 34.3% (95% confidence interval (CI) 17.8 to 47.5); for A(H3N2) 29.3% (95% CI: 8.6 to 45.3) and for B 46.3% (95% CI: 13.9 to 66.5). For those aged under 18 years, influenza A(H3N2) LAIV VE was 35% (95% CI: −29.9 to 67.5), whereas for influenza B the LAIV VE was 100% (95% CI:17.0 to 100.0). Although the VE against influenza A(H3N2) infection was low, there was still evidence of significant protection, together with moderate, significant protection against drifted circulating influenza B viruses. LAIV provided non-significant positive protection against influenza A, with significant protection against B. Further work to assess the population impact of the vaccine programme across the UK is underway.
full article
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=21237
Surveillance and outbreak report
Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results
R Pebody [SUP]1[/SUP] , F Warburton [SUP]1[/SUP] , N Andrews [SUP]1[/SUP] , J Ellis [SUP]1[/SUP] , B von Wissmann [SUP]2[/SUP] , C Robertson [SUP]3[/SUP] , I Yonova [SUP]4[/SUP] [SUP]5[/SUP] , S Cottrell [SUP]6[/SUP] , N Gallagher [SUP]7[/SUP] , H Green [SUP]1[/SUP] , C Thompson [SUP]1[/SUP] , M Galiano [SUP]1[/SUP] , D Marques [SUP]2[/SUP] , R Gunson [SUP]2[/SUP] , A Reynolds [SUP]2[/SUP] , C Moore [SUP]6[/SUP] , D Mullett [SUP]4[/SUP] [SUP]5[/SUP] , S Pathirannehelage [SUP]4[/SUP] [SUP]5[/SUP] , M Donati [SUP]1[/SUP] , J Johnston [SUP]7[/SUP] , S de Lusignan [SUP]4[/SUP] [SUP]5[/SUP] , J McMenamin [SUP]2[/SUP] , M Zambon [SUP]1[/SUP]
+ Author affiliations
1. Public Health England, England, United Kingdom
2. Health Protection Scotland, Scotland, United Kingdom
3. University of Strathclyde, Scotland, United Kingdom
4. RCGP Research and Surveillance Centre, England, United Kingdom
5. University of Surrey, England, United Kingdom
6. Public Health Wales, Wales, United Kingdom
7. Public Health Agency Northern Ireland, Northern Ireland, United Kingdom
Correspondence: Richard Pebody (richard.pebody@phe.gov.uk)
Citation style for this article: Pebody R, Warburton F, Andrews N, Ellis J, von Wissmann B, Robertson C, Yonova I, Cottrell S, Gallagher N, Green H, Thompson C, Galiano M, Marques D, Gunson R, Reynolds A, Moore C, Mullett D, Pathirannehelage S, Donati M, Johnston J, de Lusignan S, McMenamin J, Zambon M. Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results. Euro Surveill. 2015;20(36)
ii=30013. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2015.20.36.30013Received:16 June 2015; Accepted:31 August 2015
[h=4][/h]
The 2014/15 influenza season in the United Kingdom (UK) was characterised by circulation of predominantly antigenically and genetically drifted influenza A(H3N2) and B viruses. A universal paediatric influenza vaccination programme using a quadrivalent live attenuated influenza vaccine (LAIV) has recently been introduced in the UK. This study aims to measure the end-of-season influenza vaccine effectiveness (VE), including for LAIV, using the test negative case?control design. The overall adjusted VE against all influenza was 34.3% (95% confidence interval (CI) 17.8 to 47.5); for A(H3N2) 29.3% (95% CI: 8.6 to 45.3) and for B 46.3% (95% CI: 13.9 to 66.5). For those aged under 18 years, influenza A(H3N2) LAIV VE was 35% (95% CI: −29.9 to 67.5), whereas for influenza B the LAIV VE was 100% (95% CI:17.0 to 100.0). Although the VE against influenza A(H3N2) infection was low, there was still evidence of significant protection, together with moderate, significant protection against drifted circulating influenza B viruses. LAIV provided non-significant positive protection against influenza A, with significant protection against B. Further work to assess the population impact of the vaccine programme across the UK is underway.
full article
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=21237